The price-to-earnings ratio for Becton Dickinson & Co. (NYSE: BDX) is 57.15x, which is above its average ratio. Moreover, the 36-month beta value for BDX is 0.43. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BDX is 288.49M and currently, short sellers hold a 0.73% of that float. On March 22, 2024, BDX’s average trading volume was 1.49M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BDX) stock’s latest price update
Becton Dickinson & Co. (NYSE: BDX)’s stock price has increased by 1.58 compared to its previous closing price of 237.87. However, the company has seen a 1.88% increase in its stock price over the last five trading sessions. Reuters reported 2024-03-21 that Becton Dickinson said on Thursday that it will increase domestic production of medical syringes.
BDX’s Market Performance
BDX’s stock has risen by 1.88% in the past week, with a monthly drop of -1.51% and a quarterly rise of 0.42%. The volatility ratio for the week is 1.66% while the volatility levels for the last 30 days are 1.64% for Becton Dickinson & Co. The simple moving average for the past 20 days is 1.29% for BDX’s stock, with a -4.38% simple moving average for the past 200 days.
Analysts’ Opinion of BDX
Many brokerage firms have already submitted their reports for BDX stocks, with Raymond James repeating the rating for BDX by listing it as a “Outperform.” The predicted price for BDX in the upcoming period, according to Raymond James is $305 based on the research report published on July 24, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see BDX reach a price target of $295. The rating they have provided for BDX stocks is “Overweight” according to the report published on May 30th, 2023.
Piper Sandler gave a rating of “Overweight” to BDX, setting the target price at $290 in the report published on May 05th of the previous year.
BDX Trading at 1.36% from the 50-Day Moving Average
After a stumble in the market that brought BDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.91% of loss for the given period.
Volatility was left at 1.64%, however, over the last 30 days, the volatility rate increased by 1.66%, as shares sank -0.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.59% upper at present.
During the last 5 trading sessions, BDX rose by +1.88%, which changed the moving average for the period of 200-days by -4.87% in comparison to the 20-day moving average, which settled at $238.44. In addition, Becton Dickinson & Co. saw -0.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDX starting from Spoerel Thomas J, who sale 282 shares at the price of $238.29 back on Mar 14 ’24. After this action, Spoerel Thomas J now owns 2,276 shares of Becton Dickinson & Co., valued at $67,198 using the latest closing price.
Garrison Michael David, the EVP & President Medical of Becton Dickinson & Co., sale 1,239 shares at $232.46 during a trade that took place back on Dec 11 ’23, which means that Garrison Michael David is holding 7,274 shares at $288,018 based on the most recent closing price.
Stock Fundamentals for BDX
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.41 for the gross margin
The net margin for Becton Dickinson & Co. stands at 0.06. The total capital return value is set at 0.04. Equity return is now at value 5.13, with 2.47 for asset returns.
Based on Becton Dickinson & Co. (BDX), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 8.19.
Currently, EBITDA for the company is 4.71 billion with net debt to EBITDA at 3.77. When we switch over and look at the enterprise to sales, we see a ratio of 4.35. The receivables turnover for the company is 8.6for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
To wrap up, the performance of Becton Dickinson & Co. (BDX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
